Pascal Biosciences
  • Home
  • About Us
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact
Skip to content

23Sep 2020

Pascal Biosciences Confirms Specific Cannabinoids Combat Coronavirus

  • Sep 23, 2020
  • Press Releases

SEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 23, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) today announced the Company has confirmed an earlier report that certain cannabinoids block replication of SARS-CoV-2, the coronavirus that causes COVID-19.…

Read More

16Sep 2020

Pascal Biosciences to Present at International Cannabinoid Derived Pharmaceutical Summit

  • Sep 16, 2020
  • Press Releases

SEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 16, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) has been invited to present at the International Cannabinoid Derived Pharmaceutical (ICDP) Summit. Today Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements in…

Read More

14Sep 2020

Reuters article on partnership with SōRSE Technology

  • Sep 14, 2020
  • In the News

Our exciting partnership with SōRSE Technology has been featured on an article in Reuters. We invite you to read more here: https://www.reuters.com/article/us-pascal-cancer-sorse/canadas-pascal-biosciences-partners-with-sorse-to-test-cannabis-based-cancer-therapy-idUSKBN2651VC

Read More

14Sep 2020

Pascal Biosciences and SōRSE Technology Announce Partnership for Cannabinoid Drug Development and Cancer Clinical Trials

  • Sep 14, 2020
  • Press Releases

SEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 14, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and SōRSE Technology Corporation (“SōRSE”) have entered into a Collaborative Research Agreement (the “Agreement”) to advance Pascal’s PAS-393 into clinical testing. Pascal and SōRSE will…

Read More

Recent Posts

  • Pascal Biosciences Signs Term Sheet for Acquisition of THC Essentials
  • PASCAL BIOSCIENCES PLANS NEW DIRECTION TO INCLUDE CONTRACT RESEARCH
  • Pascal Biosciences First To File Patent For COVID-19 Antiviral Activity With CBD
  • Pascal Biosciences Sign Term Sheet for $2,000,000 Convertible Notes
  • Pascal Biosciences Settles Certain Outstanding Payables with Issuance of Shares and Details Share-related Compensation to Employees

Categories

  • In the News
  • Press Releases
  • Uncategorized

Archives

  • December 2022
  • June 2022
  • April 2022
  • March 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • June 2021
  • March 2021
  • January 2021
  • December 2020
  • November 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • March 2020
  • October 2019
  • September 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • July 2018
  • June 2018
  • February 2018
  • December 2017
  • September 2017
  • May 2017
  • March 2017
  • November 2016
  • October 2016
  • September 2016

About

Pascal Biosciences Inc. (TSX-V: PAS, FSE:6PB.F, OTC:PSCBF) is a biotechnology company focused on developing cannabinoid-based and targeted therapeutics to fight cancer.

Locations

USA

Fluke Hall, Suite 304
Box 352141
4000 Mason Road
Seattle, WA 98195-2141

Canada

280 7th Avenue East
Vancouver, BC V5T 0B4

Contact

Phone

206.221.3443

Email

info@pascalbiosciences.com

Investors

invest@pascalbiosciences.com

Partnering & Business Development

bd@pascalbiosciences.com

Let's Connect

  • Facebook
  • Twitter
  • Linked
  • Home
  • Company
  • Programs
  • News
  • Investors
  • Contact
  • Disclaimer
  • Legal Notices

© Copyright 2023 Pascal Biosciences Inc. All rights reserved.   Seattle Website Design by Jordan Crown Design

  • Home
  • About Us
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact

‹ › ×